Oxidative stress and its biomarkers in systemic lupus erythematosus

Journal of Biomedical Science

Bishnuhari Paudyal²  Swapan K Nath³  Sangita Sah¹  Nidhi Mahajan⁵  Dilip Shah⁴ 

[1] Department of Biochemistry, JNMC, Belgaum, Karnataka, India;Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA;Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA;Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA;Department of Biochemistry, Panjab University, Chandigarh 160014, India

关键词: Systemic lupus erythematosus;    Antioxidant therapy;    Biomarkers;    Oxidative stress;   

Others  :  820963
DOI  :  10.1186/1423-0127-21-23

 received in 2013-11-17, accepted in 2014-03-06,  发布年份 2014

【 摘 要 】

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease whose etiology remains largely unknown. The uncontrolled oxidative stress in SLE contributes to functional oxidative modifications of cellular protein, lipid and DNA and consequences of oxidative modification play a crucial role in immunomodulation and trigger autoimmunity. Measurements of oxidative modified protein, lipid and DNA in biological samples from SLE patients may assist in the elucidation of the pathophysiological mechanisms of the oxidative stress-related damage, the prediction of disease prognosis and the selection of adequate treatment in the early stage of disease. Application of these biomarkers in disease may indicate the early effectiveness of the therapy. This review is intended to provide an overview of various reactive oxygen species (ROS) formed during the state of disease and their biomarkers linking with disease. The first part of the review presents biochemistry and pathophysiology of ROS and antioxidant system in disease. The second part of the review discusses the recent development of oxidative stress biomarkers that relates pathogenesis in SLE patients and animal model. Finally, this review also describes the reported clinical trials of antioxidant in the disease that have evaluated the efficacy of antioxidant in the management of disease with ongoing conventional therapy.

【 授权许可】

   
2014 Shah et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Graham KL, Utz PJ: Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005, 17:513-517.
• [2]Shah D, Kiran R, Wanchu A, Bhatnagar A: Soluble granzyme B and cytotoxic T lymphocyte activity in the pathogenesis of systemic lupus erythematosus. Cell Immunol 2011, 269:16-21.
• [3]Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J: Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17:371-375.
• [4]Kurien BT, Scofield RH: Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008, 7:567-573.
• [5]Ahsan H, Ali A, Ali R: Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 2003, 131:398-404.
• [6]Kim-Howard X, Sun C, Molineros JE, Maiti AK, Chandru H, Adler A, Wiley GB, Kaufman KM, Kottyan L, Guthridge JM, Rasmussen A, Kelly J, Sánchez E, Raj P, Li QZ, Bang SY, Lee HS, Kim TH, Kang YM, Suh CH, Chung WT, Park YB, Choe JY, Shim SC, Lee SS, Han BG, Olsen NJ, Karp DR, Moser K, Pons-Estel BA, et al.: Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Hum Mol Genet 2014, 23:1656-1668.
• [7]Cordova EJ, Velazquez-Cruz R, Centeno F, Baca V, Orozco L: The NRF2 gene variant, −653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus 2010, 19:1237-1242.
• [8]Warchol T, Lianeri M, Wudarski M, Lacki JK, Jagodzinski PP: Catalase -262C > T polymorphism in systemic lupus erythematosus in Poland. Rheumatol Int 2008, 28:1035-1039.
• [9]Kiyohara C, Washio M, Horiuchi T, Asami T, Ide S, Atsumi T, Kobashi G, Takahashi H, Tada Y: Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of cigarette smoking and systemic lupus erythematosus in a Japanese population. Scand J Rheumatol 2012, 41:103-109.
• [10]Ollier W, Davies E, Snowden N, Alldersea J, Fryer A, Jones P, Strange R: Association of homozygosity for glutathione-S-transferase GSTM1 null alleles with the Ro+/La- autoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheum 1996, 39:1763-1764.
• [11]Mansour RB, Lassoued S, Gargouri B, El Gaid A, Attia H, Fakhfakh F: Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 2008, 37:103-108.
• [12]Ben Mansour R, Lassoued S, Elgaied A, Haddouk S, Marzouk S, Bahloul Z, Masmoudi H, Attia H, Aifa MS, Fakhfakh F: Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010, 39:247-253.
• [13]Jovanovic V, Abdul Aziz N, Lim YT, Ng Ai Poh A, Jin Hui Chan S, Ho Xin Pei E, Lew FC, Shui G, Jenner AM, Bowen L, McKinney EF, Lyons PA, Kemeny MD, Smith KG, Wenk MR, Macary PA: Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus. PLoS One 2013, 8:e55639.
• [14]Shah D, Kiran R, Wanchu A, Bhatnagar A: Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett 2010, 129:7-12.
• [15]Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, Horkko S, Witztum JL: Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005, 52:192-200.
• [16]Tewthanom K, Janwityanuchit S, Totemchockchyakarn K, Panomvana D: Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. J Pharm Pharm Sci 2008, 11:30-34.
• [17]Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M: Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999, 26:318-324.
• [18]Lopez LR, Simpson DF, Hurley BL, Matsuura E: OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann N Y Acad Sci 2005, 1051:313-322.
• [19]Shah D, Sah S, Wanchu A, Wu MX, Bhatnagar A: Altered redox state and apoptosis in the pathogenesis of systemic lupus erythematosus. Immunobiology 2013, 218:620-627.
• [20]Shah D, Kiran R, Wanchu A, Bhatnagar A: Relationship between T lymphocyte subsets and cortisol in systemic lupus erythematosus. Kathmandu Univ Med J (KUMJ) 2009, 7:213-219.
• [21]Shah D, Aggarwal A, Bhatnagar A, Kiran R, Wanchu A: Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic Res 2011, 45:559-567.
• [22]Shah D, Wanchu A, Bhatnagar A: Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 2011, 216:1010-1017.
• [23]Perl A, Gergely P Jr, Banki K: Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus. Int Rev Immunol 2004, 23:293-313.
• [24]Perl A: Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol 2013, 9:674. 686
• [25]Turi S, Nemeth I, Torkos A, Saghy L, Varga I, Matkovics B, Nagy J: Oxidative stress and antioxidant defense mechanism in glomerular diseases. Free Radic Biol Med 1997, 22:161-168.
• [26]Hassan SZ, Gheita TA, Kenawy SA, Fahim AT, El-Sorougy IM, Abdou MS: Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis 2011, 14:325-331.
• [27]Kurien BT, Scofield RH: Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol 2006, 44:349-356.
• [28]Taysi S, Gul M, Sari RA, Akcay F, Bakan N: Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002, 40:684-688.
• [29]Serban MG, Balanescu E, Nita V: Lipid peroxidase and erythrocyte redox system in systemic vasculitides treated with corticoids. Effect of vitamin E administration. Rom J Intern Med 1994, 32:283-289.
• [30]Turgay M, Durak I, Erten S, Ertugrul E, Devrim E, Avci A, Turgay F: Oxidative stress and antioxidant parameters in a Turkish group of patients with active and inactive systemic lupus erythematosus. APLAR J Rheumatol 2007, 10:101-106.
• [31]Segal BM, Thomas W, Zhu X, Diebes A, McElvain G, Baechler E, Gross M: Oxidative stress and fatigue in systemic lupus erythematosus. Lupus 2012, 21:984-992.
• [32]Bae SC, Kim SJ, Sung MK: Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus. Rheumatol Int 2002, 22:238-243.
• [33]Abou-Raya A, El-Hallous D, Fayed H: 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. Clin Invest Med 2004, 27:306-311.
• [34]Mohan IK, Das UN: Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus. Prostaglandins Leukot Essent Fatty Acids 1997, 56:193-198.
• [35]Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Ayudhya DPN: The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. J Clin Pharm Ther 2009., 9999
• [36]Morgan PE, Sturgess AD, Davies MJ: Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. Free Radic Res 2009, 43:117-127.
• [37]Morgan PE, Sturgess AD, Hennessy A, Davies MJ: Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. Free Radic Res 2007, 41:1301-1312.
• [38]Zhang Q, Ye DQ, Chen GP: [Study on the relationship between protein oxidation and disease activity in systemic lupus erythematosus]. Zhonghua Liu Xing Bing Xue Za Zhi 2008, 29:181-184.
• [39]Zhang Q, Ye DQ, Chen GP, Zheng Y: Oxidative protein damage and antioxidant status in systemic lupus erythematosus. Clin Exp Dermatol 2010, 35:287-294.
• [40]Ahsan H: 3-Nitrotyrosine: a biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions. Hum Immunol 2013, 74:1392-1399.
• [41]Lunec J, Herbert K, Blount S, Griffiths HR, Emery P: 8-Hydroxydeoxyguanosine. A marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett 1994, 348:131-138.
• [42]Evans MD, Cooke MS, Akil M, Samanta A, Lunec J: Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Commun 2000, 273:894-898.
• [43]Maeshima E, Liang XM, Otani H, Mune M, Yukawa S: Effect of environmental changes on oxidative deoxyribonucleic acid (DNA) damage in systemic lupus erythematosus. Arch Environ Health 2002, 57:425-428.
• [44]Ho CY, Wong CK, Li EK, Tam LS, Lam CW: Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003, 42:117-122.
• [45]Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A: Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998, 18:41-43.
• [46]Turrens JF, Boveris A: Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980, 191:421-427.
• [47]Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979, 59:527-605.
• [48]Alam K, Moinuddin , Jabeen S: Immunogenicity of mitochondrial DNA modified by hydroxyl radical. Cell Immunol 2007, 247:12-17.
• [49]Vignais PV: The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002, 59:1428-1459.
• [50]Li KJ, Wu CH, Hsieh SC, Lu MC, Tsai CY, Yu CL: Deranged bioenergetics and defective redox capacity in T lymphocytes and neutrophils are related to cellular dysfunction and increased oxidative stress in patients with active systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:548516.
• [51]Govender P, Romero F, Shah D, Paez J, Ding SY, Liu L, Gower A, Baez E, Aly SS, Pilch P, Summer R: Cavin1; a regulator of lung function and macrophage phenotype. PLoS One 2013, 8:e62045.
• [52]Ahmad R, Rasheed Z, Ahsan H: Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol 2009, 31:388-396.
• [53]Murphy MP, Packer MA, Scarlett JL, Martin SW: Peroxynitrite: a biologically significant oxidant. Gen Pharmacol 1998, 31:179-186.
• [54]Mena S, Ortega A, Estrela JM: Oxidative stress in environmental-induced carcinogenesis. Mutat Res 2009, 674:36-44.
• [55]Shadyro OI, Yurkova IL, Kisel MA: Radiation-induced peroxidation and fragmentation of lipids in a model membrane. Int J Radiat Biol 2002, 78:211-217.
• [56]Al-Shobaili HA, Al Robaee AA, Alzolibani A, Khan MI, Rasheed Z: Hydroxyl radical modification of immunoglobulin g generated cross-reactive antibodies: its potential role in systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord 2011, 4:11-19.
• [57]Garg DK, Moinuddin , Ali R: Hydroxyl radical modification of polyguanylic acid: role of modified guanine in circulating SLE anti-DNA autoantibodies. Immunol Invest 2003, 32:187-199.
• [58]Rimbach G, Hohler D, Fischer A, Roy S, Virgili F, Pallauf J, Packer L: Methods to assess free radicals and oxidative stress in biological systems. Arch Tierernahr 1999, 52:203-222.
• [59]Hartley DP, Kroll DJ, Petersen DR: Prooxidant-initiated lipid peroxidation in isolated rat hepatocytes: detection of 4-hydroxynonenal- and malondialdehyde-protein adducts. Chem Res Toxicol 1997, 10:895-905.
• [60]Calingasan NY, Uchida K, Gibson GE: Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer’s disease. J Neurochem 1999, 72:751-756.
• [61]Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
• [62]Shah D, Sah S, Nath SK: Interaction between glutathione and apoptosis in systemic lupus erythematosus. Autoimmun Rev 2013, 12:741-751.
• [63]Al-Shobaili HA, Al Robaee AA, Alzolibani AA, Rasheed Z: Antibodies against 4-hydroxy-2-nonenal modified epitopes recognized chromatin and its oxidized forms: role of chromatin, oxidized forms of chromatin and 4-hydroxy-2-nonenal modified epitopes in the etiopathogenesis of SLE. Dis Markers 2012, 33:19-34.
• [64]Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Paulsen H, Verhagen H, Astley SB: Biomarkers. Mol Aspects Med 2002, 23:101-208.
• [65]Toyoda K, Nagae R, Akagawa M, Ishino K, Shibata T, Ito S, Shibata N, Yamamoto T, Kobayashi M, Takasaki Y, Matsuda T, Uchida K: Protein-bound 4-hydroxy-2-nonenal: an endogenous triggering antigen of antI-DNA response. J Biol Chem 2007, 282:25769-25778.
• [66]Halliwell B: Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991, 91:14S-22S.
• [67]Sies H: Role of reactive oxygen species in biological processes. Klin Wochenschr 1991, 69:965-968.
• [68]Lozovoy MA, Simao AN, Oliveira SR, Iryioda TM, Panis C, Cecchini R, Dichi I: Relationship between iron metabolism, oxidative stress, and insulin resistance in patients with systemic lupus erythematosus. Scand J Rheumatol 2013, 42:303-310.
• [69]Schafer FQ, Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001, 30:1191-1212.
• [70]Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C: Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A 1998, 95:3071-3076.
• [71]Messina JP, Lawrence DA: Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol 1989, 143:1974-1981.
• [72]Suwannaroj S, Lagoo A, Keisler D, McMurray RW: Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 2001, 10:258-265.
• [73]Johnson F, Giulivi C: Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005, 26:340-352.
• [74]Jones DP, Eklow L, Thor H, Orrenius S: Metabolism of hydrogen peroxide in isolated hepatocytes: relative contributions of catalase and glutathione peroxidase in decomposition of endogenously generated H2O2. Arch Biochem Biophys 1981, 210:505-516.
• [75]Aebi H: Catalase in vitro. Methods Enzymol 1984, 105:121-126.
• [76]Gamble SC, Wiseman A, Goldfarb PS: Selenium-dependent glutathione peroxidase and other selenoproteins: their synthesis and biochemical roles. J Chem Technol Biotech 1999, 68:123-134.
• [77]Sen CK: Cellular thiols and redox-regulated signal transduction. Curr Top Cell Regul 2000, 36:1-30.
• [78]Halliwell B, Whiteman M: Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004, 142:231-255.
• [79]Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem 2006, 52:601-623.
• [80]Eruslanov E, Kusmartsev S: Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 2010, 594:57-72.
• [81]Spengler MI, Svetaz MJ, Leroux MB, Bertoluzzo SM, Parente FM, Bosch P: Lipid peroxidation affects red blood cells membrane properties in patients with systemic lupus erythematosus. Clin Hemorheol Microcirc 2013.
• [82]Uchida K: 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003, 42:318-343.
• [83]Cracowski JL, Durand T, Bessard G: Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002, 23:360-366.
• [84]Bevan RJ, Durand MF, Hickenbotham PT, Kitas GD, Patel PR, Podmore ID, Griffiths HR, Waller HL, Lunec J: Validation of a novel ELISA for measurement of MDA-LDL in human plasma. Free Radic Biol Med 2003, 35:517-527.
• [85]Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU: 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxid Redox Signal 1999, 1:255-284.
• [86]Wang G, Li H, Firoze Khan M: Differential oxidative modification of proteins in MRL+/+ and MRL/lpr mice: increased formation of lipid peroxidation-derived aldehyde-protein adducts may contribute to accelerated onset of autoimmune response. Free Radic Res 2012, 46:1472-1481.
• [87]Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF: Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010, 62:2064-2072.
• [88]Morrow JD, Scruggs J, Chen Y, Zackert WE, Roberts LJ 2nd: Evidence that the E2-isoprostane, 15-E2t-isoprostane (8-iso-prostaglandin E2) is formed in vivo. J Lipid Res 1998, 39:1589-1593.
• [89]Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA: Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol 2013, 1:483-491.
• [90]Basu S: Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 2004, 38:105-122.
• [91]Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, Shintani A, Yu C, Stein CM: Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus 2007, 16:195-200.
• [92]Shacter E: Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000, 32:307-326.
• [93]Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R: Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003, 329:23-38.
• [94]Zaremba T, Olinski R: [Oxidative DNA damage–analysis and clinical significance]. Postepy Biochem 2010, 56:124-138.
• [95]Tagesson C, Kallberg M, Klintenberg C, Starkhammar H: Determination of urinary 8-hydroxydeoxyguanosine by automated coupled-column high performance liquid chromatography: a powerful technique for assaying in vivo oxidative DNA damage in cancer patients. Eur J Cancer 1995, 31A:934-940.
• [96]Kasai H: A new automated method to analyze urinary 8-hydroxydeoxyguanosine by a high-performance liquid chromatography-electrochemical detector system. J Radiat Res 2003, 44:185-189.
• [97]Saito S, Yamauchi H, Hasui Y, Kurashige J, Ochi H, Yoshida K: Quantitative determination of urinary 8-hydroxydeoxyguanosine (8-OH-dg) by using ELISA. Res Commun Mol Pathol Pharmacol 2000, 107:39-44.
• [98]Shimoi K, Kasai H, Yokota N, Toyokuni S, Kinae N: Comparison between high-performance liquid chromatography and enzyme-linked immunosorbent assay for the determination of 8-hydroxy-2′-deoxyguanosine in human urine. Cancer Epidemiol Biomarkers Prev 2002, 11:767-770.
• [99]Hu CW, Wu MT, Chao MR, Pan CH, Wang CJ, Swenberg JA, Wu KY: Comparison of analyses of urinary 8-hydroxy-2′-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Rapid Commun Mass Spectrom 2004, 18:505-510.
• [100]Wei YH, Lu CY, Wei CY, Ma YS, Lee HC: Oxidative stress in human aging and mitochondrial disease-consequences of defective mitochondrial respiration and impaired antioxidant enzyme system. Chin J Physiol 2001, 44:1-11.
• [101]Townsend DM, Tew KD, Tapiero H: The importance of glutathione in human disease. Biomed Pharmacother 2003, 57:145-155.
• [102]Vipartene D, Iasiulevichute L, Butkene B, Valiukene K, Keturkene A, Redaitene E: [Pro- and antioxidant blood system in patients with rheumatoid arthritis and systemic lupus erythematosus]. Ter Arkh 2006, 78:10-14.
• [103]Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A: Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum 2013, 65:1313-1318.
• [104]Attia FM, Maaty A, Kalil FA: Circulating endothelial cells as a marker of vascular dysfunction in patients with systemic lupus erythematosus by real-time polymerase chain reaction. Arch Pathol Lab Med 2011, 135:1482-1485.
• [105]Kudaravalli J: Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. Indian J Pharmacol 2011, 43:311-315.
• [106]Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, Miklossy G, Jimah J, Doherty E, Tily H, Francis L, Garcia R, Dawood M, Yu J, Ramos I, Coman I, Faraone SV, Phillips PE, Perl A: N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012, 64:2937-2946.
• [107]Tzang BS, Hsu TC, Kuo CY, Chen TY, Chiang SY, Li SL, Kao SH: Cystamine attenuates lupus-associated apoptosis of ventricular tissue by suppressing both intrinsic and extrinsic pathways. J Cell Mol Med 2012, 16:2104-2111.